论文部分内容阅读
临床试验证明,补充铬或铬的生物活性形式—糖耐量因子(GTF)可降低Ⅰ型及Ⅱ型糖尿病与糖耐量异常病人的血糖,改善血脂异常及增强对胰岛素的敏感性。Glinsmann与Mertz对4例糖尿病病人每天供给180～1000μg的三价铬,结果3例血糖明显降低,1例血糖轻微降低。Anderson对76名正常者人进行双盲、交叉研究,其中18名糖耐量受损者补铬后糖耐量明显改善。有人对13例应用胰岛素和口服降糖药治疗不敏感的病人口服铬治疗2～4个月,结果血糖由14.4mmol/L降至6.6mmol/L,其中5例降糖药物减量。Offenbacher对24名老人进行高铬酵母和低铬酵母的补铬试验,结果高铬酵母组糖耐量和胰岛素的敏感性改善,胆固醇降低,而低铬酵母组无效。国内梁荩忠对胰岛素控制欠佳的糖尿病病人加用三价钠治疗,2个月后病
Clinical trials have shown that glucose-tolerance factor (GTF), a bioactive form of chromium or chromium supplementation, has been shown to reduce blood glucose, improve dyslipidemia, and increase insulin sensitivity in patients with type I and II diabetes and impaired glucose tolerance. Glinsmann and Mertz supplied 180-1000 μg of trivalent chromium per day to four patients with diabetes, resulting in a significant decrease in blood glucose in three patients and a slight decrease in blood glucose in one patient. Anderson conducted a double-blind, crossover study of 76 normal individuals, of whom 18 impaired glucose tolerance impaired glucose tolerance. Some patients were treated with insulin and oral hypoglycemic drug-insensitive patients treated with chromium for 2 to 4 months, resulting in blood glucose from 14.4mmol / L to 6.6mmol / L, of which 5 cases of hypoglycemic agents reduction. Offenbacher performed chromate tests on 24 elderly people with high-chromium yeast and low-chromium yeast, resulting in improved glucose tolerance and insulin sensitivity in high-chromium yeast, lower cholesterol, and no effect in the low-chromium yeast group. Domestic Liangzhong loyal insulin poor control of patients with added sodium trivalent sodium treatment, 2 months after the disease